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Abstract
Background: Tigecycline, a first-in-class broad-spectrum glycylcycline antibiotic, has broad-spectrum in vitro activity
against bacteria commonly encountered in complicated intra-abdominal infections (cIAIs), including aerobic and
facultative Gram-positive and Gram-negative bacteria and anaerobic bacteria. In the current trial, tigecycline was
evaluated for safety and efficacy vs. imipenem/cilastatin in hospitalized Chinese patients with cIAIs.
Methods: In this phase 3, multicenter, open-label study, patients were randomly assigned to receive IV tigecycline
or imipenem/cilastatin for ≤2 weeks. The primary efficacy endpoints were clinical response at the test-of-cure visit
(12-37 days after therapy) for the microbiologic modified intent-to-treat and microbiologically evaluable
populations. Because the study was not powered to demonstrate non-inferiority between tigecycline and
imipenem/cilastatin, no formal statistical analysis was performed. Two-sided 95% confidence intervals (CIs) were
calculated for the response rates in each treatment group and for differences between treatment groups for
descriptive purposes.
Results: One hundred ninety-nine patients received ≥1 dose of study drug and comprised the modified intent-to-
treat population. In the microbiologically evaluable population, 86.5% (45 of 52) of tigecycline- and 97.9% (47 of
48) of imipenem/cilastatin-treated patients were cured at the test-of-cure assessment (12-37 days after therapy); in
the microbiologic modified intent-to-treat population, cure rates were 81.7% (49 of 60) and 90.9% (50 of 55),
respectively. The overall incidence of treatment-emergent adverse events was 80.4% for tigecycline vs. 53.9% after
imipenem/cilastatin therapy (P < 0.001), primarily due to gastrointestinal-related events, especially nausea (21.6% vs.
3.9%; P < 0.001) and vomiting (12.4% vs. 2.0%; P = 0.005).
Conclusions: Clinical cure rates for tigecycline were consistent with those found in global cIAI studies. The overall
safety profile was also consistent with that observed in global studies of tigecycline for treatment of cIAI, as well as
that observed in analyses of Chinese patients in those studies; no novel trends were observed.
Trial Registration: ClinicalTrials.gov NCT00136201
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The management of complicated intra-abdominal infec-
tions (cIAIs) remains a challenge to physicians because
of their polymicrobial nature coupled with the high risk
of sequelae and mortality in severely ill patients with
these infections [1-3]. While most infections contain a
m i x t u r eo fa e r o b i ca n da n a e r o b i cb a c t e r i aw i t hap r e -
ponderance of Enterobacteriaceae (e.g., Escherichia coli)
[1,2], resistant and uncommon organisms (e.g., Entero-
coccus, Staphylococcus, Enterobacter, Pseudomonas and
Candida spp.) are often isolated in patients with noso-
comial infection or tertiary peritonitis [4].
Selection of empiric antimicrobial therapy must con-
sider the likelihood of encountering isolates that possess
multiple resistance factors (e.g., extended-spectrum beta-
lactamases [ESBLs], vancomycin-resistant enterococci
[VRE]) [1,2]. Recently published treatment guidelines
recommend broad-spectrum monotherapy or combina-
tion regimens (e.g., carbapenem monotherapy, third- or
fourth-generation cephalosporins or fluoroquinolones
plus metronidazole) for high-risk patients with severe or
postoperative nosocomial intra-abdominal infections
wherein polymicrobial infections and/or resistant flora
are more prevalent [1,2]. Notably, inappropriate antibio-
tic choices have been linked to delayed clinical resolu-
tion, longer hospital stay, and an increased risk of
mortality [5,6]. While adjunctive antimicrobial therapy is
vital to achieving desired outcomes, surgical intervention
is essential in the management of patients with cIAIs.
Tigecycline, a first-in-class expanded broad-spectrum
glycylcycline antibiotic approved for use in patients with
cIAIs, overcomes the 2 major mechanisms of resistance
to tetracycline (i.e., drug-specific efflux pump acquisition
and ribosomal protection) [7,8]. Tigecycline has broad-
spectrum in vitro activity against bacteria commonly
encountered in cIAIs, including aerobic and facultative
Gram-positive and Gram-negative bacteria and anaero-
bic bacteria [9-11]. Furthermore, tigecycline has in vitro
activity against multidrug-resistant bacteria such as
VRE, ESBL- and carbapenemase-producing enteric
Gram-negative bacteria, and methicillin-resistant S. aur-
eus (MRSA) [12-14]. Tigecycline also exhibits linear
pharmacokinetics and has a large volume of distribution,
suggesting extensive tissue penetration [15].
Two global phase 3 double-blind trials, which com-
pared the efficacy of tigecycline and imipenem/cilastatin
in hospitalized patients with cIAIs, have demonstrated
that tigecycline is efficacious for this condition [16]. Imi-
penem/cilastatin was chosen as the comparative agent
because it has a wide spectrum of activity, it is effective
in the treatment of hospitalized patients with intra-
abdominal infections, and is widely available and used in
the treatment of cIAI. In the current trial, tigecycline
monotherapy was evaluated for safety and efficacy vs.
imipenem/cilastatin in hospitalized Chinese patients
with cIAI as a supplement to the 2 double-blinded pivo-
tal global studies in cIAI [16].
Methods
Study design and treatment regimens
This study was a phase 3, multicenter, open-label trial of
hospitalized Chinese patients at least 18 years of age
who were candidates for or had undergone a laparot-
omy, laparoscopy, or percutaneous drainage of an intra-
abdominal abscess and had a known or suspected diag-
nosis of cIAI. Specific enrollment criteria are outlined in
Table 1. Following approval of the study protocol by the
institutional review board or ethical review committee at
each participating center, each patient or his or her legal
representative provided written informed consent prior
to undergoing any study procedures.
Patients were randomly assigned using a computerized
enrollment system in a 1:1 ratio to receive tigecycline
(initial 100-mg dose given by intravenous [IV] infusion
over a 30-minute period, followed by 50 mg IV every 12
hours) or IV imipenem/cilastatin (500 mg/500 mg every
6 hours or dose-adjusted based on weight and creatinine
clearance). Patients were to receive study drug for up to
2 weeks, unless deemed a treatment failure after at least
4 doses of tigecycline or 8 doses of imipenem/cilastatin.
Baseline aerobic and anaerobic cultures from the pri-
mary intra-abdominal site of infection and two sets of
blood cultures were obtained within 24 hours of the
first dose of study drug.
Clinical and microbiologic evaluations
At serial visits throughout the study, the clinical status
of the patient’s intra-abdominal infection was assessed
based upon the presence or absence of the following
signs and symptoms: fever; localized or diffuse abdom-
inal wall rigidity or involuntary guarding; abdominal
tenderness or pain; ileus or hypoactive bowel sounds;
nausea or vomiting. The clinical response to study drug
was determined by the investigator at the test-of-cure
(TOC) visit (12-37 days after therapy) and categorized
as cure, failure, or indeterminate.
Microbiologic response by patient was categorized at
the TOC visit as eradication, persistence, superinfection
(i.e., the emergence of a new isolate was documented at
the site of infection with worsening signs and symptoms
of infection), or indeterminate. The microbiologic
response for each baseline isolate at the TOC visit was
categorized as eradication, persistence, or indeterminate.
Safety and tolerability assessments
All patients who received at least one dose of study drug
were evaluated for safety. Safety was assessed from clinical
observations and findings from serial electrocardiograms
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urinalysis tests. Adverse events (AEs) were recorded
throughout the study period, up to and including the
TOC visit or 14 days after last dose of study medication
(whichever was longer), and were subjectively rated by the
investigator as to their severity and relationship to the
study drug. Investigators also recorded whether the AE
resulted in temporary or permanent discontinuation and
whether any remedial action was taken. Serious AEs
(SAEs; i.e., those that were life-threatening, led to prolon-
gation of the existing hospitalization, caused persistent or
significant disability or incapacity, led to cancer, or death)
were also recorded.
Statistical analysis
Three primary populations of patients were assessed for
safety, clinical, and bacteriologic outcomes; the modified
intent-to-treat (mITT), microbiologic modified ITT (m-
mITT), and the microbiologically evaluable (ME) popu-
lations. ITT patients who received at least one dose of
study drug were included in the mITT population.
Patients in the mITT population who had clinical
evidence of complicated intra-abdominal infection com-
prised the clinical-mITT (c-mITT) population. The
m-mITT population consisted of patients in the c-mITT
population who had ≥1 isolate identified at the baseline
assessment. Clinically evaluable (CE) patients were c-
mITT patients who met all inclusion/exclusion criteria;
did not receive concomitant antibiotics after the baseline
intra-abdominal culture was obtained through the test-
of-cure visit; received no more than 1 dose of a prohib-
ited antibacterial treatment after the baseline intra-
abdominal culture was obtained but before the first dose
of study drug; received at least 5 days of study drug and
between 80% and 120% of planned doses; had a test-of-
cure visit 12 to 37 days after the last dose of study drug.
Those patients included in the microbiologically evalu-
able (ME) population were CE patients who had at least
one identifiable baseline bacterial isolate(s) taken from
the primary site of infection that was susceptible to both
study drugs and who had a microbiologic response
assigned, i.e., eradication, persistence, or superinfection,
at the TOC visit.
This trial was designed to enroll 200 patients. By
assuming an evaluability rate of 50%, this would allow
for the evaluation of 100 ME patients. The expected
percentage of patients with a favorable clinical response
(cure) was 70% at the TOC assessment. With a sample
Table 1 Enrollment criteria
Inclusion* Exclusion
†
Men and non-pregnant, non-lactating women ≥18 years of age who
required a surgical procedure for a complicated intra-abdominal infection
(cIAI)
cIAI defined as the following:
An intra-abdominal abscess (including liver and spleen) that developed in
a postsurgical patient after receiving standard antibacterial therapy (i.e., at
least 48 hours, but not more than 5 days of antibiotics);
Appendicitis complicated by perforation and/or a periappendiceal
abscess;
Perforated diverticulitis complicated by abscess formation or fecal
contamination;
Complicated cholecystitis with evidence of perforation or empyema;
perforation of a gastric or duodenal ulcer with symptoms exceeding 24
hours;
Purulent peritonitis or peritonitis associated with fecal contamination;
Perforation of the large or small intestine with abscess or fecal
contamination, or traumatic bowel perforation with symptoms lasting at
least 12 hours before an operation
Preoperative suspicion of a diagnosis of spontaneous bacterial peritonitis,
simple cholecystitis, gangrenous cholecystitis without rupture, simple
appendicitis, acute suppurative cholangitis, pancreatic abscess, or
infected necrotizing pancreatitis;
Acute Physiologic and Chronic Health Evaluation (APACHE) II score
greater than 30;
Surgical procedure requiring that fascia or deep muscular layers be left
open or expectation of planned abdominal re-exploration either in or
out of the operating room;
Use of immunosuppressive therapy that would decrease the patient’s
ability to eradicate the infection, including use of high-dose
corticosteroids (e.g., 40 mg or more of prednisone or an equivalent per
day for more than 3 weeks before randomization) or known diagnosis of
acquired immunodeficiency syndrome;
Current intra-abdominal infection known to be caused by one or more
bacterial isolates not susceptible to either of the study drugs (e.g., P.
aeruginosa, Proteus mirabilis);
Active or treated leukemia or systemic malignancy that requires
chemotherapy, immunotherapy, radiation therapy, or antineoplastic
therapy within the 3 months before enrollment, or any metastatic
malignancy to the abdomen with life expectancy < 6 months;
Presence of any uncontrolled central nervous system disease;
Significant hepatic disease (i.e., aspartate aminotransferase [AST] or
alanine aminotransferase [ALT] level > 10 times the upper limit of normal
[ULN] or total bilirubin value > 3 times the ULN) or acute hepatic failure
or acute decompensation of chronic hepatic failure;
Significant renal disease (i.e., calculated creatinine clearance < 41 mL/
min/1.73 m
2 after adequate hydration);
Neutropenia with absolute neutrophil count < 1000 mm
3 (however,
neutrophil counts as low as 500 cells/mm
3 permitted if secondary to the
acute infectious process);
Concomitant treatment with ganciclovir
*Patients had to satisfy the inclusion criteria to be considered eligible for study participation
†Patients were ineligible for study participation if they had one or more of the listed exclusions
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35 patients showed a favorable clinical response, then
the 2-sided exact 95% CI would equal 55.4, 82.1.
The primary efficacy endpoints were clinical
response at the TOC visit for the m-mITT and ME
populations. Microbiological response at the TOC visit
by patient and isolate was performed as a secondary
analysis. Because the study was not powered to
demonstrate non-inferiority between tigecycline and
imipenem/cilastatin, no formal statistical analysis was
performed for the primary and secondary efficacy end-
points of this study. Two-sided 95% confidence inter-
vals (CIs) were calculated for the response rates in
each treatment group for descriptive purposes using
the “exact” method of Clopper and Pearson. Two-sided
95% CIs for differences between groups were calcu-
lated based on the asymptotic method corrected for
continuity, except for differences in subgroup analyses
where the Wilson score method corrected for continu-
ity was used. Secondary efficacy analyses included the
determination of susceptibility to tigecycline (MIC50,
MIC90) and the development of decreased susceptibil-
ity (at least a 4-fold increase in MIC from baseline).
Susceptibility was analyzed by using the Fisher exact
test.
A post-hoc Cochran-Mantel-Haenszel analysis (strati-
fied by protocol) was performed on the 2 co-primary
efficacy endpoints to evaluate equality across the current
trial and the 2 global cIAI studies [16]. The Breslow-Day
test was used to evaluate equality across the strata with
a P value of < 0.05 indicating statistical significance
from study to study with respect to clinical response.
The Global Biostatistics and Programming Depart-
ment of Wyeth Research performed all statistical
analyses.
Results
The disposition of Chinese patients participating in this
trial and the analysis populations are summarized in
Figure 1. Overall, 199 patients received at least 1 dose of
a study drug and comprised the mITT (safety)
population.
The demographic and baseline medical characteristics
for the mITT patients were comparable between the 2
treatment groups (Table 2) with the exception that tige-
cycline-treated patients were statistically significantly
older (P = 0.021) and the severity of intra-abdominal ill-
ness was statistically significantly greater in the tigecy-
cline cohort (mean APACHE II score was 5.1 for
tigecycline vs. 4.1 for imipenem/cilastatin; P =0 . 0 3 8 ) .
Complicated appendicitis was the most common intra-
abdominal infection diagnosis in both groups (76.3%
vs. 76.5% for tigecycline and imipenem/cilastatin,
respectively).
Clinical efficacy
For the ME population, clinical cure rates were 86.5%
for tigecycline and 97.9% for imipenem/cilastatin (95%
CI for the difference, -23.5, 0.7) (Table 3). All patients
had APACHE II scores ≤15. Corresponding clinical cure
rates for the m-mITT population were 81.7% and 90.9%,
respectively (95% CI for the difference, -23.4, 4.9). Clini-
cal cure rates stratified by monomicrobial and polymi-
crobial infections are found in Table 3. For complicated
appendicitis, by far the most frequent diagnosis in this
study, clinical cure rates at the TOC visit for the ME
population were 87.0% for tigecycline and 100.0% for
imipenem/cilastatin (95% CI for the difference, -27.0,
-0.6) (Table 4).
These findings in Chinese patients were similar to
results in 2 global double-blind clinical trials [16],
wherein the clinical response of tigecycline was found to
be non-inferior to imipenem/cilastatin (Figure 2). The
results of the Breslow-Day test indicate that there was
no significant difference in clinical response across the 3
studies in the ME (P = 0.0979) or the m-mITT popula-
tion (P = 0.1655) for the current study in Chinese
patients (Study 316) and the 2 pivotal global studies
(Study 301 and Study 306).
A total of 6 tigecycline- and 3 imipenem/cilastatin-
treated patients in the ME population had positive pre-
therapy blood culture results, including 7 isolates in
tigecycline patients and 4 in imipenem/cilastatin
patients. All blood culture isolates were Gram-negative
rods. All 9 patients with bacteremia were reported as
having a clinical cure/bacteriologic eradication at the
TOC visit.
Microbiologic efficacy
For the ME population, presumed eradication of intra-
abdominal isolates at the patient level based upon clini-
cal response mirrored the clinical cure rates: 86.5% for
tigecycline- and 97.9% for imipenem/cilastatin-treated
patients (Table 5). Eradication rates stratified by mono-
microbial and polymicrobial infection are also summar-
ized in Table 5.
Eradication rates at the TOC visit for the most com-
mon types of isolated intra-abdominal pathogens are
outlined in Table 6 for the two treatment groups. For E.
coli, the most commonly isolated bacteria, eradication
rates were 88.1% for tigecycline vs. 97.7% for imipenem/
cilastatin. There were no obvious differences in eradica-
tion rates of other aerobic and anaerobic bacteria,
although the number of isolates per species was small,
making comparisons difficult.
Overall, MIC values for tigecycline against the most
commonly isolated aerobes and anaerobes was ≤2.0 μg/
mL. For E. coli (n = 86), MIC50 and MIC90 values were
0.125 μg/mL and 0.5 μg/mL for tigecycline, respectively,
Chen et al. BMC Infectious Diseases 2010, 10:217
http://www.biomedcentral.com/1471-2334/10/217
Page 4 of 11and 0.25 μg/mL and 0.5 μg/mL for imipenem/cilastatin,
respectively. For patients in the tigecycline group who
had persistent E. coli infections (5 isolates; 11.9%), MIC
values ranged from 0.125 to 0.5 μg/mL. Bacterial sus-
ceptibilities to tigecycline were consistent with clinical
responses, and no isolates from later cultures with a
decreased susceptibility (≥4-fold increase in MIC from
baseline) to tigecycline were identified.
Safety and tolerability
The mITT population received a median of 5 and 6
days of tigecycline or imipenem/cilastatin treatment,
Figure 1 Analysis populations and patient disposition: Tigecycline (TGC) vs. imipenem-cilastatin (I/C) in complicated intra-abdominal
infections.
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Page 5 of 11respectively. The overall range for the number of days of
therapy was 2 to 14 days. The overall incidence of treat-
ment-emergent AEs was 80.4% for tigecycline vs. 53.9%
for imipenem/cilastatin therapy (P < 0.001); this differ-
ence between treatment groups was primarily due to
gastrointestinal-related events, primarily nausea and
vomiting (Table 7). The overall percentage of subjects
with study drug-related AEs was significantly higher in
the tigecycline group compared to the imipenem/cilasta-
tin treatment arm (55.7% vs. 41.2%; P < 0.05). The dif-
ference stemmed primarily from between-group
differences in nausea (20.6% tigecycline vs. 2% imipe-
nem/cilastatin; P < 0.001) and vomiting (tigecycline
10.3% vs. imipenem/cilastatin 1%; P =0 . 0 0 4 ) .M o s tA E s
Table 2 Demographic and baseline characteristics (mITT population)
Tigecycline N = 97 Imipenem/cilastatin N = 102 P value*
Mean ± SD age, years 46.8 ± 18.2 41.0 ± 16.7 0.021
Sex, n (%) male 65 (67.0) 71 (69.6) 0.694
Mean ± SD weight, kg 63.2 ± 10.9 64.7 ± 11.1 0.335
Mean ± SD creatinine clearance, mL/min 100.9 ± 37.5 108.8 ± 37.1 0.138
APACHE II score 0.038
Mean ± SD 5.1 ± 3.9 4.1 ± 2.7
Median (range) 4.0 (0.0 - 21.0) 4.0 (0.0 - 12.0)
Primary intra-abdominal diagnosis, n (%) 0.509
Complicated appendicitis 74 (76.3) 78 (76.5)
Complicated cholecystitis 5 (5.2) 7 (6.9)
Perforated duodenal ulcer 3 (3.1) 7 (6.9)
Peritonitis due to perforation of small intestine 6 (6.2) 2 (2.0)
Peritonitis due to perforation of large intestine 4 (4.1) 2 (2.0)
Perforated gastric ulcer 1 (1.0) 2 (2.0)
Complicated cholangitis 2 (2.1) 0 (0)
Post-traumatic peritonitis 1 (1.0) 1 (1.0)
Liver abscess 1 (1.0) 2 (2.0)
Perforated stomach 0 (0) 1 (1.0)
NA = not available
*Categorical baseline demographic and medical variables were analyzed using the Fisher exact test. Continuous variables were compared using a one-way
analysis of variance (ANOVA) model with treatment as a factor.
Table 3 Clinical cure rates* by analysis population at test-of-cure visit
Tigecycline Imipenem/cilastatin Difference
(Tigecycline-Imipenem/cilastatin)
Population N % (95% CI) N % (95% CI) % (95% CI)
ME 45/52 86.5
(74.2, 94.4)
47/48 97.9
(88.9, 99.9)
-11.4
(-23.5, 0.7)
Monomicrobial 30/33 90.9
(75.7, 98.1)
25/26 96.2
(80.4, 99.9)
-5.2
(-22.0, 13.7)
Polymicrobial 15/19 78.9
(54.4, 93.9)
22/22 100.0
(84.6, 100.0)
-21.1
(-46.1, 2.2)
m-mITT 49/60 81.7
(69.6, 90.5)
50/55 90.9
(80.0, 97.0)
-9.2
(-23.4, 4.9)
Monomicrobial 32/38 84.2
(68.7, 94.0)
27/29 93.1
(77.2, 99.2)
-8.9
(-26.0, 10.7)
Polymicrobial 17/22 77.3
(54.6, 92.2)
23/26 88.5
(69.8, 97.6)
-11.2
(-35.8, 13.0)
CE 67/77 87.0
(77.4, 93.6)
83/87 95.4
(88.6, 98.7)
-8.4
(-18.3, 1.5)
c-mITT 78/97 80.4
(71.1, 87.8)
88/98 89.8
(82.0, 95.0)
-9.4
(-20.3, 1.6)
*Clinical responses defined as: Cure–the course of study drug and the initial intervention (operative and/or radiologically guided drainage procedure) resolved the
intra-abdominal infectious process; Failure–the patient required additional antibacterial therapy other than the study drug, the patient required additional surgical
or radiologic intervention to cure the infection, death due to infection occurred after 48 hours of therapy or a treatment-related adverse event (AE),o rt h e
patient received an extended course of study drug (i.e., > 120% of the planned number of doses); and Indeterminate–the patient was lost to follow-up, or died
within 48 hours after the first dose of study drug for any reason, or died after 48 hours because of noninfectious-related reasons (as judged by the investigator).
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clinically important.
Nine SAEs were recorded during the study period
(8 [8.2%] tigecycline vs. 1 [1.0%] imipenem/cilastatin) (P =
0.016). The most frequently reported SAE was abnormal
healing (3 [3.1%] tigecycline vs. 0 imipenem/cilastatin; P =
0.114). There were no significant differences between the
treatment groups in the specific types of SAEs experi-
enced. Overall, these SAEs were not considered by the
investigator to be related to study medication.
Two (2.1%) tigecycline- and 2 (2.0%) imipenem/cilas-
tatin-treated patients had treatment stopped early
because of an adverse event. In the tigecycline group, 1
patient discontinued therapy because of gastrointestinal
hemorrhage and shock and 1 because of nausea. Both
imipenem/cilastatin-treated patients discontinued treat-
ment secondary to diarrhea.
A single death was reported during the study, which
was unrelated to study medication. This tigecycline-trea-
ted patient, a 74-year-old man who underwent a colost-
omy, died of septic shock and multiple organ failure 1
day after his first dose of study medication.
The only clinically relevant laboratory test abnormality
was that significantly more Chinese patients treated with
tigecycline had a low platelet count (i.e., platelet count ≤
100 × 10
9/L) compared with the imipenem/cilastatin-
treated patients (11.5% vs. 2.0%, P = 0.009). Further
examination of 7 patients who had platelet counts ≤ 50
×1 0
9/L revealed that these patients either had thrombo-
cytopenia at baseline, or thrombocytopenia was attribu-
ted by the investigator to infection/sepsis. Mean platelet
count increases observed at the TOC assessment were
similar in both treatment arms. There were no signifi-
cant differences between the treatment groups with
respect to mean changes in individual ECG parameters,
nor were there any AEs associated with prolonged QT
interval after either treatment reported.
Discussion
This analysis of hospitalized Chinese patients demon-
strated that open-label tigecycline monotherapy (100 mg
initial dose, followed by 50 mg q12 hours) was effective
for the treatment of cIAIs. The 199 patients included in
the mITT population had mild to moderately severe
intra-abdominal infections, as described by a mean
APACHE II score of 4.6. For patients comprising the
Table 4 Clinical cure rates by diagnosis at test-of-cure visit (ME population)
Tigecycline Imipenem/cilastatin Difference (Tigecycline-Imipenem/cilastatin)
Diagnosis N % (95% CI) N % (95% CI) % (95% CI)
Complicated appendicitis 40/46 87.0
(73.7, 95.1)
45/45 100
(92.1, 100.0)
-13.0
(-27.0, -0.6)
Complicated cholecystitis 2/2 100.0
(15.8, 100.0)
0/0 NA NA
Peritonitis 2/3 66.7
(9.4, 99.2)
2/3 66.7
(9.4, 99.2)
0.0
(-62.7, 62.7)
Gastric/duodenal perforation 1/1 100.0
(2.5, 100.0)
0/0 NA NA
NA - not available
Figure 2 Tigecycline clinical cure rates compared to previous
intra-abdominal studies (301, 306): (a) microbiologically
evaluable (ME) and (b) microbiologic modified intent-to-treat
(m-mITT) populations. Error bars indicate 95% confidence intervals,
unweighted and calculated using the method of Clopper and
Pearson.
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from 81.7% to 86.5% for tigecycline vs. 90.9% to 97.9%
for imipenem/cilastatin at the test-of-cure visit. All ME
patients with bacteremia in both treatment groups were
clinically cured; however, the absolute number of such
patients was small. Tigecycline-treated patients with
polymicrobial infection tended to have lower clinical
cure rates compared with patients who had monomicro-
bial infection. Although approximately three-quarters of
patients had complicated appendicitis, tigecycline was
effective across the range of clinical diagnoses.
Microbiologic responses paralleled clinical outcomes
for both tigecycline and imipenem/cilastatin in Chinese
patients. In the ME population, the baseline organisms
were eradicated in 86.5% of tigecycline-treated patients
and 97.9% of patients treated with imipenem/cilastatin
at the TOC visit. Satisfactory eradication of commonly
encountered aerobic and anaerobic intestinal bacteria
after both treatments was also observed. Eradication
rates for E. coli, the most commonly isolated bacteria,
were 88.1% for tigecycline vs. 97.7% for imipenem/cilas-
tatin. Although other Gram-negative enterics (e.g.,
Table 5 Microbiologic response by patient at test-of-cure visit (ME population)
Tigecycline Imipenem/cilastatin Difference
(Tigecycline-Imipenem/cilastatin)
N % (95% CI) N % (95% CI) % (95% CI)
Overall
Eradication 45/52 86.5
(74.2, 94.4)
47/48 97.9
(88.9, 99.9)
-11.4
(-23.5, 0.7)
Persistence 7/52 13.5
(5.6, 25.8)
1/48 2.1
(0.1, 11.1)
Superinfection 0/52 0
(0.0, 6.8)
0/48 0
(0.0, 7.4)
Monomicrobial
Eradication 30/33 90.9
(75.7, 98.1)
25/26 96.2
(80.4, 99.9)
-5.2
(-22.0, 13.7)
Persistence 3/33 9.1
(1.9, 24.3)
1/26 3.8
(0.1, 19.6)
Superinfection 0/33 0
(0.0, 10.6)
0/26 0
(0.0, 13.2)
Polymicrobial
Eradication 15/19 78.9
(54.4, 93.9)
22/22 100.0
(84.6, 100.0)
-21.1
(-46.1, 2.2)
Persistence 4/19 21.1
(6.1, 45.6)
0/22 0
(0.0, 15.4)
Superinfection 0/19 0
(0.0, 17.6)
0/22 0
(0.0, 15.4)
Table 6 Microbiologic eradication at the isolate level: selected baseline isolates at test-of-cure visit (ME population)
Tigecycline (N = 52) Imipenem/cilastatin (N = 48)
Baseline Isolate N E ER (%) N E ER (%)
Total 83 69 83.1 75 74 98.7
Gram negative aerobic bacteria 56 48 85.7 59 58 98.3
E. coli 42 37 88.1 44 43 97.7
Other Enterobacteriaceae 8 6 75.0 9 9 100
Non-fermentative Gram-negative bacilli 6 5 83.3 6 6 100
Gram positive aerobic bacteria 15 12 80.0 8 8 100
Enterococcus spp. 10 8 80.0 5 5 100
Streptococcus spp. 5 4 80.0 2 2 100
Staphylococcus spp. 0 0 0 1 1 100
Anaerobe 12 9 75.0 8 8 100
Bacterioides spp. 7 5 71.4 6 6 100
Other anaerobe 5 4 80.0 2 2 100
E = eradication (presumed), and ER = eradication rate.
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tococcus spp., Enterococcus spp.), and anaerobic bacteria
(e.g., B. fragilis, Bacteroides spp.) were isolated in small
numbers, tigecycline generally eradicated most of these
pathogens. Overall, these data provide in vivo evidence
that tigecycline has broad-spectrum activity against
common bacterial etiologies associated with cIAIs
[9,10,14,17,18].
Tigecycline monotherapy was generally well tolerated
in this study population, even though the overall inci-
dence of treatment-emergent AEs was significantly
higher after tigecycline therapy (80.4%) compared with
imipenem/cilastatin (53.9%; P < 0.001). The main reason
for the increased rates of AEs was gastrointestinal, with
tigecycline-treated patients having a two-fold higher rate
than those given imipenem/cilastatin (P = 0.001). In par-
ticular, nausea and vomiting occurred significantly more
often (5-6 fold) after tigecycline therapy. To the con-
trary, diarrhea occurred in higher rates among imipe-
nem/cilastatin recipients (P > 0.05). Gastrointestinal-
related adverse events rarely led to early discontinuation
of either therapy, however, as only one tigecycline
patient stopped treatment early due to nausea, as did
two imipenem/cilastatin-treated patients secondary to
diarrhea. Of interest, nearly two-fold more patients trea-
ted with tigecycline had bilirubinemia compared with
Table 7 Common treatment-emergent adverse events (≥3% in either group)
Body System
Adverse Event
Tigecycline (N = 97) Imipenem/cilastatin (N = 102) P value
a
Any adverse event 78 (80.4) 55 (53.9) < 0.001
Body as a whole 11 (11.3) 8 (7.8) 0.473
Chest pain 3 (3.1) 1 (1.0) 0.359
Digestive system 35 (36.1) 16 (15.7) 0.001
Abdominal distension 7 (7.2) 2 (2.0) 0.094
Diarrhea 5 (5.2) 9 (8.8) 0.409
Nausea 21 (21.6) 4 (3.9) < 0.001
Vomiting 12 (12.4) 2 (2.0) 0.005
Hemic and lymphatic system 23 (23.7) 21 (20.6) 0.613
Anemia 3 (3.1) 3 (2.9) 1.000
Coagulation disorder 4 (4.1) 0 (0) 0.055
Monocytosis 1 (1.0) 6 (5.9) 0.119
Prothrombin time prolonged 1 (1.0) 4 (3.9) 0.369
Thrombocythemia 6 (6.2) 6 (5.9) 1.000
Thrombocytopenia 5 (5.2) 1 (1.0) 0.111
Metabolic and nutritional 37 (38.1) 35 (34.3) 0.658
ALT/SGPT increased 3 (3.1) 5 (4.9) 0.722
AST/SGOT increased 6 (6.2) 7 (6.9) 1.000
Amylase increased 8 (8.2) 9 (8.8) 1.000
Bilirubinemia 21 (21.6) 12 (11.8) 0.085
Healing abnormal 7 (7.2) 6 (5.9) 0.779
Hyperglycemia 1 (1.0) 4 (3.9) 0.369
Hypocalcemia 6 (6.2) 5 (4.9) 0.763
Hypokalemia 1 (1.) 4 (3.9) 0.369
Hyponatremia 3 (3.1) 1 (1.0) 0.359
Hypophosphatemia 5 (5.2) 5 (4.9) 1.000
Hypoproteinemia 10 (10.3) 11 (10.8) 1.000
Lipase increased 3 (3.1) 0 (0) 0.114
Respiratory system 3 (3.1) 3 (2.9) 1.000
Cough increased 3 (3.1) 1 (1.0) 0.359
Skin and appendages 1 (1.0) 4 (3.9) 0.369
Rash 1 (1.0) 4 (3.9) 0.369
Adverse event associated with miscellaneous factors 4 (4.1) 6 (5.9) 0.748
Local reaction to procedure 4 (4.1) 6 (5.9) 0.748
AST/SGOT = aspartate aminotransferase/serum glutamic oxaloacetic transaminase.
ALT/SGOT = alanine aminotransferase/serum glutamic oxaloacetic transaminase.
aBetween-group comparisons of adverse events were analyzed by using the Fisher exact test. Significant between-group difference at P ≤ 0.05 level.
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11.8%; P = 0.085). While bilirubinemia has been
observed in prior studies of tigecycline to treat cIAI, the
rates in the current study were higher than those
observed in patients enrolled in previous trials (16); in
each instance, however, the presence of mitigating fac-
tors confound determinations of a relationship between
the study drugs and changes in bilirubin levels. Overall,
safety/tolerability findings described herein were consis-
tent with the original global trials [16] and support pre-
vious safety data from phase 2 and 3 studies [16,19-24].
Significantly more subjects in the tigecycline treatment
arm had SAEs than subjects in the imipenem/cilastatin
arm (8.2% vs. 1.0%, P = 0.016); however, there were no
significant differences between the treatment groups in
t h es p e c i f i ct y p eo fS A Er e p o rted. The most frequently
reported SAE was abnormal healing. No unusual or
novel adverse events were reported in Chinese patients
after tigecycline monotherapy.
A major limitation of the current trial is that it was not
powered for a formal statistical analysis of noninferiority.
In addition, the study design was open-label (unblinded),
adding to the confounding factors affecting comparisons
of efficacy within the study. Accordingly, it is inappropri-
ate to draw conclusions about the efficacy of tigecycline
on the basis of the results of this study alone. However,
the results of our study in Chinese patients is consistent
with the efficacy findings from 2 global randomized, dou-
ble-blind studies [16], and the same dose administration
schedule was used across the 3 studies to treat hospita-
lized patients with cIAI. In study 301, 80.6% of tigecy-
cline-treated patients and 82.4% of imipenem/cilastatin-
treated patients in the ME population were clinically
cured, as were 73.5% of tigecycline-treated patients and
78.2% of imipenem/cilastatin-treated patients in the m-
mITT population. In the overall ME population of study
306, 91.3% of tigecycline-treated patients and 89.9% of
imipenem/cilastatin-treated patients were clinically
cured; in the m-mITT population, 86.6% of tigecycline-
treated subjects and 84.6% of imipenem/cilastatin-treated
subjects were clinically cured. Furthermore, the 2 global
studies included sites that enrolled Chinese patients [16].
Formal statistical analyses in the global studies demon-
strated that tigecycline met the statistical criteria of non-
inferiority to imipenem/cilastatin for the primary end-
point of clinical response (cure or failure) in the co-pri-
mary populations at the TOC assessment, and the results
of primary clinical cure or failure analyses for tigecycline
in the study described herein mirrored the results in
these pivotal cIAI studies.
Conclusion
In summary, tigecycline monotherapy appears to be
both effective and safe for the treatment of cIAI in
Chinese patients. Both the efficacy and safety analyses
for this study are consistent with the profile of tigecy-
cline elucidated in the pivotal trials (Study 301/306)
[16]. Digestive-related AEs were significantly higher in
t h et i g e c y c l i n eg r o u p ,e s p e c i a l l yn a u s e aa n dv o m i t i n g .
With the diverse bacteriology of cIAIs and the emer-
gence of bacterial resistance, tigecycline provides an
empiric monotherapy option with coverage against a
broad range of Gram-positive and Gram-negative aero-
bic and anaerobic bacteria, including resistant isolates
based upon in vitro data.
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